US court permits early launch of generic version of Teva MS drug

WASHINGTON - Teva Pharmaceutical Industries' multiple sclerosis drug Copaxone will lose its patent protection in 2014 rather than 2015 because of a ruling from a US appeals court Friday.
The US Court of Appeals for the Federal Circuit issued its decision in a patent fight between Teva and rivals Sandoz and Mylan Inc.
The result is that a generic version of Copaxone can be launched in May 2014, a year early.
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy